Key Points The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. 10 stocks we like better than Replimune Group › Biotech stocks can be volatile, a tendency that was very much in Replimune Group's (NASDAQ: REPL) favor on Monday. The biotech's stock had more than doubled in late-session action, thanks to some very positive news on the regulatory front. Its rise was easily eclipsing the S&P 500 index, which at that point was ...

Group 1 - The article discusses the strategy of investing in biotech stocks that have significantly declined in value following negative news, suggesting that such stocks may present buying opportunities [1] - The author has a background in Corporate Finance and has transitioned to full-time investment analysis, focusing on Canadian small cap stocks [1] - The author expresses a desire to engage in freelance opportunities related to Canadian or American listed stocks, indicating a commitment to high-quality analysis [1] Group 2 - There is a disclosure stating that the author does not currently hold any positions in the mentioned companies but may consider initiating a long position in ARVN within the next 72 hours [2] - The article emphasizes that past performance does not guarantee future results and that no specific investment recommendations are being made [3]